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Vertical human immunodeficiency virus (HIV) infection has decreased in industrialized countries in recent decades, but there are no
studies on themechanisms of HIV transmission among infected children in Spain. Our aimwas to study the characteristics and trends
of diagnoses of vertically HIV-infected children in Spain from 2004 to 2013.
Vertically HIV-infected children were selected if they were diagnosed from 2004 to 2013, were aged 0 to 18 years old, and were
included in the Cohort of the Spanish Pediatric HIV Network (CoRISpe). Demographic, clinical, immunological, and virological data at
diagnosis were obtained. The rate of diagnoses of vertically HIV-infected children was calculated as the number of cases per 100,000
inhabitants. Obstetric data of mothers of Spanish children and prophylaxis at childbirth and postpartum were obtained.
A total of 218 HIV-infected children were included in the study. Of this sample, 182 children (83.5%) were perinatally HIV infected,
and 125 out of those 182 children (68.7%) were born in Spain. The vertically HIV-infected Spanish children were diagnosed earlier
and were in better clinical and immunological condition at diagnosis than were foreign children. The rate of vertically HIV-infected
children declined from 0.09 in 2004 to 0.03 in 2013 due to the decrease in the rate of children born in Spain (0.08 in 2004 vs 0.01 in
2013). A total of 60 out of 107 mothers (56.1%) of Spanish children were diagnosed at or after childbirth. However, this number
declined between 2004 and 2013.
The rate of new HIV diagnoses of vertically HIV-infected children decreased significantly between 2004 and 2013 from 0.09 to 0.03
per 100,000 inhabitants.
Abbreviations: 3TC = lamivudine, AACC = Autonomous Communities, AZT = zidovudine, cART = combination antiretroviral
therapy, CDC = Centers for Diseases Control and Prevention, COHERE = Collaboration of Observational HIV Epidemiological
Research Europe, CoRISpe = Cohort of the Spanish Pediatric HIV Network, EPPICC = The European Pregnancy and Pediatric HIV
Cohort Collaboration, HIV = human immunodeficiency virus, IDU = intravenous drug use, NVP = nevirapine, PENTA = Pediatric
European Network for Treatment of AIDS, PMTCT = prevention of mother-to-child transmission, SINIVIH = information systems on
new HIV diagnoses.
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Approximately, 35 million people worldwide are living with
HIV-infected children diagnosed in Spain, total and stratified by
origin of the children; to analyze clinical, immunological, andhuman immunodeficiency virus (HIV), and 2.1 million new
infections were reported in 2013.[1] Most individuals living with
HIV live in sub-Saharan Africa and have been infected mainly
through sexual contact. A total of 29,157 new HIV infections
(3278 of which were in Spain) within 30 European Union/
European Economic Association countries were reported in
2013.[2,3] Due to the prevention of mother-to-child transmission
(PMTCT) beginning in 1994 and the use of combination
antiretroviral therapy (cART) since 1996, vertical HIV infection
has decreased to 1% to 2% in newborns in industrialized
countries such as Spain.[4–11] In 2007, the Spanish Health
Ministry recommended HIV screening for pregnant women, and
in 2007 and 2013, the Spanish Clinical Guide recommended HIV
screening for all pregnant women within the first 3 months of
pregnancy and in the third trimester if the previous test was
negative.[12,13] Thus, of the 3278 new diagnoses reported in
Spain in 2013, only 10 newborns (0.3%) were vertically HIV
infected.[3]
Epidemiological surveillance of HIV in Spain is based on 2
systems: the National Registry of AIDS, including all AIDS cases
from the beginning of the HIV epidemic in Spain (1981) recorded
in the AIDS Spanish Registry of Autonomous Communities
(AACC), and the Information Systems on New HIV Diagnoses
(SINIVIH) (2000), including the new HIV diagnoses recorded in
the AACC Surveillance Systems.[3] The SINIVIH collects
epidemiological, clinical, and immunological data of children
at HIV diagnosis. However, this system does not have any data
on trends describing the incidence of new diagnoses of vertically
HIV-infected children.
In 2008, an open, multicenter, retrospective, and prospective
study called Cohort of the Spanish Pediatric HIV Network
(CoRISpe), which collaborates actively with the Spanish HIV
HGM BioBank, was founded in accordance with Spanish law
on the protection of personal data.[14–16] The availability of
CoRISpe electronic data has been critical in the research of
vertically HIV-infected children since the first years of the
pandemic. CoRISpe has collected epidemiological, clinical,
immunological, virological, analytical, and antiretroviral pro-
spective data from HIV-infected children and adolescents, with
follow-up in Spanish pediatric units since 2008, as well as
retrospective data from children since 1995.[14] Its aim is to
facilitate the conducting of high-quality research studies on HIV-
infected children. Until December 2013, the CoRISpe has
included data from 1079 HIV-infected children and adolescents
from 56 hospitals of 16 AACC, representing almost the entire
geographical territory of Spain. We have obtained interesting
results from these data, as seen in several of our published articles.
Moreover, CoRISpe has collaborated for many years with
various European cohorts (e.g., the European Pregnancy and
Pediatric HIV Cohort Collaboration, EPPICC; Collaboration of
Observational HIV Epidemiological Research Europe, CO-
HERE; and Pediatric European Network for Treatment of AIDS,
PENTA).
Our main objectives were to describe the characteristics of the
children included in the CoRISpewhowere newly diagnosedwith
HIV infection, as well as the trends in the rate of new diagnoses
of vertically HIV-infected children from 2004 to 2013. Our
specific objectives were as follows: to describe the mechanism of
transmission of newHIV diagnoses in children and adolescents in
Spain; to describe epidemiological trends in the rates of vertically2
virological differences in mother-to-child HIV-infected children,
by origin (children born in Spain vs children born in other
countries); and to describe the features of the mothers of the
children born in Spain in terms of pregnancy and prophylaxis at
childbirth and in the newborns, stratifying by mothers’ origin
(Spanish mothers vs foreign mothers).2. Patients and methods
2.1. Children selection
HIV-infected children included in the CoRISpe, diagnosed in
Spain from January 2004 to December 2013 between the ages of
0 and 18 years, were enrolled in our study. HIV-infected children
were excluded if they were diagnosed in foreign countries before
coming to Spain.Written informed consent was obtained from all
patients, and the Ethics Committee of the participating hospitals
approved the study.2.2. Description of newly diagnosed HIV children and
analysis of vertically HIV-infected children
The following data were collected from children at the time of
HIV diagnosis: epidemiological data (birth country, sex, and
birth and diagnosis information), clinical data (following the
Centers for Diseases Control and Prevention [CDC] guides),
immunological data (CD4+ T lymphocyte count and percentage),
and virological data (viral load [VL] in copies/mL).2.3. Calculating the pediatric HIV rate in the population
Vertically HIV-infected children and adolescents were selected
from the children included in our study. Population projections in
Spain were obtained from the National Statistics Institute on the
first day of July every year to calculate rates, using the general
population of each year as the denominator. The total rate of new
diagnoses from 2004 to 2013 was calculated by dividing the
number of vertically HIV-infected children by the sum of the
corresponding population in the study period (i.e., number of
cases/100,000 inhabitants). The rates by origin (children born
in Spain vs foreign children) were also calculated, with
the corresponding population in the study period as the
denominator.2.4. Characteristics of mothers of vertically HIV-infected
children
Data were analyzed from the mothers of the vertically HIV-
infected children selected for the study sample. Children born in
foreign countries were excluded from this analysis. The data
collected from these mothers included the following: HIV
mechanism of transmission, HIV diagnosis period (before and
during pregnancy and childbirth), cART taken during pregnancy,
VL at childbirth, mode of delivery, prophylaxis received at
childbirth (mothers) and various gestational ages (newborn), and
breastfeeding of the newborns by these mothers. Mothers with
HIV diagnosed within 14 days before or after childbirth were
considered to be late diagnoses. The results were stratified by
mothers’ origin: mothers born in Spain versus mothers born in
foreign countries (Fig. 1). VL below 50copies/mL was considered
undetectable.
Figure 1. Characteristics of mothers of vertically HIV-infected children. HIV=human immunodeficiency virus.
Jiménez de Ory et al. Medicine (2017) 96:39 www.md-journal.com2.5. Statistical analysis
Results involving qualitative variables were expressed as
proportions, whereas results involving quantitative variables
were expressed as medians and interquartile ranges. Hypothesis
tests were not performed because the data collected for the study
were population data.Table 1





Age at diagnosis and Medicine 1.1 (0.2–3.9) 4.6 (4.2–6.4) 16.4 (1
Sex, N (%)
Males 86 (47.3) 7 (77.8) 3 (3
Females 96 (52.7) 2 (22.2) 6 (6
Born in Spain, N (%)
Yes 125 (68.7) 0 (0) 3 (3
No 57 (31.3) 9 (100) 6 (6
CDC at diagnosis, N (%)
N-A 115 (63.2) 4 (44.4) 7 (7
B 35 (19.2) 2 (22.2) 1 (1
C 31 (17) 3 (33.3) 1 (1
Unknown 1 (0.5) 0 (0) 0 (0
Immunological status at diagnosis, N (%)
1 69 (37.9) 2 (22.2) 4 (4
2 58 (31.9) 2 (22.2) 4 (4
3 48 (26.4) 5 (55.6) 1 (1
Unknown 7 (3.8) 0 (0) 0 (0
%CD4 at diagnosis, median (IQR) 24.1 (15–37) 8 (5.3–16) 27 (1
CD4/mm3 at diagnosis, median (IQR) 965 (472–2124) 187 (71–697) 472 (3
Log. VL at diagnosis, median (IQR) 5.1 (4.5–5.7) 5.4 (4.4–6.1) 4.3 (4
CDC=centers for diseases control and prevention; CoRISpe=Cohort of the Spanish Pediatric HIV Netw
3
3. Results
3.1. Description of new HIV children and adolescent
diagnoses
A total of 285 new cases of HIV-infected children and adolescents





(mother with unknown HIV status)
=9 N=7 N=11
5.5–16.6) 10.9 (9.9–12) 9 (6.5–12.2)
3.3) 6 (85.7) 5 (45.5)
6.6) 1 (14.3) 6 (54.5)
3.3) 5 (71.4) 0 (0)
6.7) 2 (28.6) 11 (100)
7.7) 1 (14.3) 5 (45.5)
1.1) 2 (28.6) 4 (36.3)
1.1) 4 (57.1) 2 (18.2)
) 0 (0) 0 (0)
4.4) 1 (14.3) 4 (36.3)
4.4) 1 (14.3) 1 (9.1)
1.1) 5 (71.4) 6 (54.5)
) 0 (0.0) 0 (0)
8–29) 9 (1.7–12.9) 11 (8.5–22)
68–675) 148 (23–270) 296 (121–739)
.1–4.9) 4.7 (4.4–4.9) 5.4 (5.2–5.8)
ork; HIV=human immunodeficiency virus, IQR= interquartile range, VL= viral load.
Figure 2. Rates of new HIV diagnoses by vertical transmission in Spain per year of diagnosis. HIV=human immunodeficiency virus.
Table 2
Demographic, clinical, immunological, and virological profile of the




Age at diagnosis and Medicine 0.4 (0.1–2) 4 (2.2–6.9)
Sex, N (%)
Jiménez de Ory et al. Medicine (2017) 96:39 Medicinecases, 51 children were excluded from the study because they
were diagnosed with HIV infection in other countries before
coming to Spain. Sixteen children were excluded because they
were diagnosed in AACC or provinces with no hospitals
participating in the CoRISpe or were first followed in hospitals
out of the CoRISpe. Of the remaining children included in the
study, 182 out of 218 (83.5%) were vertically HIV infected, 9 out
of 218 (4.1%) acquiredHIV infection through blood transfusion,
9 out of 218 (4.1%) were HIV infected by sexual transmission,
and 18 out of 218 (7.4%) had an unknown route of transmission.
Seven out of 18 mothers (3.2%) were HIV negative. In 11 out of
18 cases (5%), the HIV status of the mother was unknown.
Vertically HIV-infected children were diagnosed at an earlier age
than were children infected by other routes. Children infected
with HIV through blood transfusion and those with an unknown
mechanism of infection (and with unknown HIV status of
mother) were born in foreign countries, mainly in sub-Saharan
Africa (8 out of 9 [88.9%] and 9 out of 11 [81.8%], respectively),
and Latin America (1 out of 9 [11.1%] and 1 out of 11 [9.1%],
respectively). Children and adolescents infected with HIV
through sexual contact mainly came from Latin America
(6 out of 9, or 66.7%). Vertically HIV-infected children had
higher CD4+ T lymphocyte counts and percentage values than did
children infected through other routes of transmission (Table 1).
Four out of 218 children died, 3 who died at 1, 5, and 7 months
after being diagnosed with HIV, and 1 who died at 7 months and
was diagnosed postmortem. Of these 4 children who died, 3 were
vertically HIV infected, while the mechanism of transmission
of the remaining child was unknown. The cause of death of the
3 vertically HIV-infected children was Pneumocystis jirovecii
pneumonia, whereas the other child passed away from secondary
pulmonary hypertension.Male 57 (45.6) 29 (50.9)
Female 68 (54.4) 28 (49.1)
CDC at diagnosis, N (%)
N-A 89 (71.2) 26 (45.6)
B 20 (16) 15 (26.3)
C 15 (12) 16 (28.1)
Unknown 1 (0.8) 0 (0)
Immunological status at diagnosis, N (%)
1 60 (48) 9 (15.8)
2 31 (24.8) 27 (47.4)
3 28 (22.4) 20 (35.1)
Unknown 6 (4.8) 1 (1.8)
%CD4 at diagnosis, median (IQR) 31.9 (20–43) 18 (11.5–24.2)
CD4/mm3 at diagnosis, median (IQR) 1433 (620–2408) 614 (315–1146)
Log. VL at diagnosis, median (IQR) 5.2 (4.5–5.8) 5 (4.5–5.6)
CDC= centers for diseases control and prevention; CoRISpe=Cohort of the Spanish Pediatric HIV
Network; HIV=human immunodeficiency virus, IQR= interquartile range, VL= viral load.3.2. Calculating the pediatric HIV rate in the population
A decrease was observed in the rate of new diagnoses by vertical
transmission per 100,000 inhabitants, from 0.09 in 2004 to 0.03
in 2013. After stratifying the rates by origin, we observed that the
rate of children from Spain decreased from 0.08 in 2004 to 0.01
in 2013, whereas the rate of foreign children was stable, from
0.01 in 2004 to 0.02 in 2013. In fact, the rate of foreign children
was higher than the rate of Spanish children for the first time in
2013 (Fig. 2).
3.3. Analysis of vertically HIV-infected children
A total of 125 out of 182 children (68.7%) were born in Spain,
while 57 out of those 182 children (31.3%) were born in foreign
countries. Although the majority of the foreign children came4
from sub-Saharan Africa (41 out of 57, or 71.9%), 6 out of 57
(10.5%) came from Europe, 5 out of 57 (8.8%) from Latin
America, 3 out of 57 (5.3%) from North Africa, and 2 out of 57
(3.5%) from Asia. Children born in foreign countries were
diagnosed later than children born in Spain (median age 4 years
vs 0.4 years, respectively), had lower CD4+ T lymphocyte counts
and percentage values (614 [18%] CD4+ T lymphocytes vs 1433
[31.9%] CD4+ T lymphocytes, respectively) and were in worse
clinical situations (54.4% vs 28%, respectively, with CDC B and
C status) and immunological situations (82.5% vs 47.2%,
respectively, with immunological status 2 and 3). However, no
differences in VL between groups were observed (Table 2).3.4. Characteristics of mothers of vertically HIV-infected
children
We analyzed a sample of 122 mothers who had a total of 125
children born in Spain (Fig. 1). Data related to the mothers’
pregnancy, childbirth, and prophylaxis were obtained for 119
out of the 122 mothers, but several cases had incomplete
information. A total of 73 out of the 119 mothers (61.3%) were
born in Spain, and 46 out of the 119 (38.7%) were immigrants.
Of these 46 immigrant mothers, 25 were from sub-Saharan
Jiménez de Ory et al. Medicine (2017) 96:39 www.md-journal.comAfrica (54.3%), 9 were fromLatin America (19.6%), 5 were from
East Europe (10.9%), 4 were from North Africa (8.7%), and
3 were from western Europe (6.5%). The proportion of mothers
from Spain was higher in the 2004 to 2008 period (59 out of
85mothers, or 69.4%) than in the 2009 to 2013 period (14 out of
34 mothers, or 41.2%).
The major routes of transmission of HIV, sexual contact, and
intravenous drug use (IDU), were the routes of transmission for
75 out of 119 mothers (63%), 50 of whom were from Spain and
25 of whom were from other countries. Of the 50 mothers from
Spain, 28 (56%) were infected by sexual transmission and 21
(42%) by IDU. A higher proportion of mothers infected by IDU
(19 out of 21, or 90.5%) were observed during the 2004 to 2008
period, compared with 2 out of 21 (9.5%) observed during the
2009 to 2013 period. All immigrant mothers were infected by
sexual transmission.
Data at the time of diagnosis were collected for 107 of the 119
(89.9%) mothers, 66 of whom were from Spain and 41 of whom
were from foreign countries. A total of 30 out of 107 mothers
(28%) were diagnosed with HIV before pregnancy, 17 out of 107
(15.9%) were diagnosed during pregnancy, 9 out of 107 (8.4%)
were diagnosed at childbirth, and 51 out of 107 (47.7%) were
diagnosed after childbirth. A higher proportion of late diagnoses
were observed in Spanish mothers compared with foreign
mothers (62.1% vs 46.3%, respectively). The number of late
diagnoses was higher (45 out of 60, or 75%) during the 2004 to
2008 period, most of which were among mothers from Spain
(33 out of 45, or 73.3%), comparedwith the 2009 to 2013 period
(15 out of 60 late diagnoses, or 25%).
Two out of 9 mothers diagnosed at childbirth (22.2%) had
a caesarean section, 2 out of 9 mothers (22.2%) received
prophylaxis at childbirth, and 7 out of 9 newborns (77.8%)
received zidovudine (AZT), lamivudine (3TC), and nevirapine
(NVP) prophylaxis postpartum.
Data related to cART were collected in 44 out of 47 mothers
diagnosed before or during pregnancy, and 26 out of these 44
mothers (59.1%) received cART. In 41 out of 47mothers, data of
prophylaxis at childbirth were available, and 34 out of these 41
mothers (82.9%) received cART prophylaxis. In the 47 mothers
diagnosed before or during pregnancy, the mode of delivery was
known, and 31 out of the 47 (56%) had a caesarean section.
Finally, data on whether newborns received prophylaxis
postpartum were available for 46 out of the 47 mothers, and
43 out of the 46 newborns (93.5%) received prophylaxis
postpartum. Regarding the children, 13 out of 43 (30.2%)
received AZT prophylaxis, and 28 out of 43 (65.1%) received
AZT and 3TC or AZT andNVP. Data on the type of prophylaxis
were not available for 2 of the children.
Data on VL near delivery were available for 21 out of
56 mothers, and only 1 out of 21 newborns had undetectable
values of VL. For these newborns, a ventouse suction cup was
used, and the newborn received postpartum prophylaxis with
zidovudine; however, although some VL tests were negative, the
child was diagnosed with HIV. No differences between mothers
from Spain and foreign countries were observed with respect to
mode of delivery, prophylaxis received at childbirth (mother) and
various gestational ages (newborn), or breastfeeding in newborns
(Table 3).4. Discussion
This is the first study that describes the characteristics of children
in Spain newly diagnosed with HIV. In our study, which includes5
data from as early as 2004, 125 out of 182 (68.7%) vertically
HIV-infected children were born in Spain, but this number
decreased twice—first from 2004 to 2008 and second from 2009
to 2013. Consistent with research conducted in other European
cohorts describing an increase in the number of foreign vertically
HIV-infected children,[17] we found that 57 of the 182 (31.3%)
vertically HIV-infected children were born in other countries but
diagnosed in Spain. The vertically HIV-infected children had
higher CD4+ T lymphocyte counts at diagnosis than children
infected with HIV by other routes of transmission. This
phenomenon occurs because once a child is diagnosed with
HIV, he or she begins to take cART, depending on his or her
clinical, immunological and virological status.[18,19,20] However,
the HIV-infected children born in foreign countries in this study
sample were diagnosed later than the children born in Spain and
therefore had more advanced disease with lower CD4+ counts.
Immigrant and Spanish children with unknown diagnosis
clinically progressed according to the natural course of the
HIV infection, with gradual decreases in CD4+ T lymphocytes.[18]
In conclusion, it is essential to diagnose the children as soon as
possible and begin cART according to clinical guidelines.[3]
We observed a decrease in the diagnosis rate of vertically HIV-
infected children from 2004 to 2013 in Spain. This findingmay be
explained by the decrease in the birth rate in Spain. However, the
diagnosis rate of vertically HIV-infected foreign children
remained stable for this period of study. The rate of vertical
HIV infection among foreign children was lower than the rate
among Spanish children, except in 2013, when the rate among
foreign children was higher. Children from foreign, high-burden
HIV countries should be offered testing upon or soon after arrival
into the country to avoid delays in diagnosis and inevitable
disease progression.[1]
Of the 75 total mothers whose HIVmechanism of transmission
was known, 21 out of 50 (42%) mothers from Spain were
infected by IDU, and 28 were infected by sexual contact; in
contrast, all 25 foreign mothers were infected by sexual
transmission. Trends in the mechanism of transmission changed
from 2004 to 2013 among Spanishmothers withHIV. During the
2004 to 2008 period, more mothers were infected with HIV by
IDU than in the 2009 to 2013 periods, during which more
mothers were infected by sexual contact. Although a downward
trend in new diagnoses of HIV by IDU has been observed in Spain
during the last 10 years, the mothers in our study sample were
infected before this downward trend occurred.[3]
Interestingly, more than the 50% of the mothers knew their
HIV status at or after childbirth, according to data from 2004 to
2008. It is important to consider that until 2007, physicians did
not request routine HIV testing for pregnant women. Therefore,
it was not possible to know the HIV status of all pregnant
women. Currently, it is mandatory to test all pregnant women for
HIV at the beginning of and during their pregnancy.[21–25] In this
way, the risk of mother-to-child transmission of new HIV
infection has decreased due to cART and detectable VL during
early pregnancy.[26–30]
There are important limitations to our study. First, some
hospitals and HIV pediatric units out of the CoRISpe could not
send data for our study. Some pediatricians of HIV-infected
children who were diagnosed and followed in hospitals were not
contacted. However, due to the number of AACC participants
(16 out of 17) in our study, the children excluded from hospitals
not participating in CoRISpe did not affect the results of our
study. The CoRISpe keeps data from 2004 to 2013 of
approximately 90% of all HIV-infected children in Spain.
Table 3
Risk factors and obstetric characteristics ofmothers of vertically HIV-infected children born in Spain, by HIV diagnosis year of the children
and origin of the mothers.
HIV mother diagnosis
2004–2008 2009–2013
Spanish Immigrants Spanish Immigrants Total
Mother HIV mechanism of transmission, N (%)
∗
N=40 N=12 N=10 N=13 N=75
IDU 19 (47.5) 0 (0) 2 (20) 0 (0) 21 (28)
Sexual 20 (50) 12 (100) 8 (80) 13 (100) 53 (70.7)
Transfusion 1 (2.5) 0 (0) 0 (0) 0 (0) 1 (1.3)
HIV mother diagnosis, N (%)
∗
N=53 N=23 N=13 N=18 N=107
Before pregnancy 15 (28.3) 5 (21.7) 5 (38.5) 5 (27.8) 30 (28)
During pregnancy 5 (9.4) 6 (26.1) 0 (0) 6 (33.3) 17 (15.9)
At birth 5 (9.4) 2 (8.7) 1 (7.7) 1 (5.6) 9 (8.4)
After birth 28 (52.8) 10 (43.5) 7 (53.8) 6 (33.3) 51 (47.7)
Mother AR treatment during pregnancy, N (%)† N=17 N=11 N=5 N=11 N=44
Yes 8 (47.1) 9 (81.8) 4 (80) 5 (45.5) 26 (59.1)
No 9 (52.9) 2 (18.2) 1 (20) 6 (54.5) 18 (40.9)
Mother VL at birth, N (%)‡ N=5 N=7 N=3 N=6 N=21
Detectable 5 (100) 7 (100) 2 (66.7) 6 (100) 20 (95.2)
Un detectable 0 (0) 0 (0) 1 (33.3) 0 (0) 1 (4.8)
Mode of delivery, N (%)† N=20 N=11 N=5 N=11 N=47
Vaginal 9 (45) 3 (27.3) 1 (20) 3 (27.3) 16 (34)
Caesarean 11 (55) 8 (72.7) 4 (80) 8 (72.7) 31 (56)
ART prophylaxis at birth, N (%)† N=15 N=11 N=5 N=10 N=41
Yes 13 (86.7) 9 (81.8) 5 (100) 7 (70) 34 (82.9)
No 2 (13.3) 2 (18.2) 0 (0) 3 (30) 7 (17.1)
ART prophylaxis in the newborn, N (%)† N=19 N=11 N=5 N=11 N=46
Yes 17 (89.5) 11 (100) 5 (100) 10 (90.9) 43 (93.5)
No 2 (10.5) 0 (0) 0 (0) 1 (9.1) 3 (6.5)
Gestacional age, N (%)
∗
N=44 N=22 N=13 N=18 N=97
Normal 27 (61.4) 16 (72.7) 11 (84.6) 13 (72.2) 67 (69.1)
Preterm 17 (38.6) 6 (27.3) 2 (15.4) 5 (27.8) 30 (30.9)
Breastfeeding, N (%)
∗
N=54 N=22 N=12 N=19 N=107
Yes 23 (42.6) 7 (31.8) 6 (50) 8 (81.2) 44 (41.1)
No 31 (57.4) 15 (68.2) 6 (50) 11 (18.8) 63 (58.9)
ART= antiretroviral therapy, HIV=human immunodeficiency virus, IDU= intravenous drug use, VL= viral load.
∗
All the mothers.
†Mothers diagnosed before or during pregnancy.
‡Mothers diagnosed before or during pregnancy or at childbirth.
Jiménez de Ory et al. Medicine (2017) 96:39 MedicineSecond, there are no Spanish cohorts of HIV-infected mothers.
Therefore, we do not know if the decrease in the rate of children
born in Spain is related to a decrease in the number of pregnancies
among Spanish women infected with HIV from 2004 to 2013.
However, we observed a decrease in the number of mothers
diagnosed at or after childbirth throughout the study period. This
decrease is probably due to the administration of HIV testing to
all pregnant women, according to the recommendations of the
Spanish Health Ministry and Clinical Guidelines. HIV-infected
mothers had access to complete PMTCT, and subsequently, new
vertical HIV infections have been prevented. Third, data were not
available for some of the mothers of vertically HIV-infected
children born in Spain, specifically the VL of mothers at birth or
near birth, because some children were born in other hospitals
before being diagnosed with HIV. However, of the 21 mothers
with available data, only 1 mother (4.8%) had an undetectable
VL at birth or near birth. Although this child could have been
infected with HIV during pregnancy, the infection was probably
caused at birth due to the use of a ventouse suction cup during the
delivery. It is important to emphasize that assisted birth must be
avoided even though control of VL is optimal. In this case,
prophylaxis in the newborn with more than 1 drug must be used,
as established by protocol in the case of mothers with detectable
VLs during pregnancy.6
In conclusion, the rate of newHIV diagnoses of vertically HIV-
infected children decreased significantly from 2004 to 2013, from
0.09 to 0.03 per 100,000 inhabitants. Improved access to
PMTCT measures has resulted in a decline in new infections in
Spanish children. Immigrant children, especially from high-
burden HIV countries, should be offered HIV testing so that
infected children may be identified at less advanced stages of
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